AstraZeneca: Truqap approved for breast cancer in Japan
The approval by Japan's Ministry of Health, Labor and Welfare (MHLW) was based on the results of a phase III trial published in the New England Journal of Medicine.
' Breast cancer is the most common cancer among women in Japan, and innovative new treatment options are urgently needed. Today's approval of Truqap [...] represents a significant step forward', commented Dave Fredrickson, Executive Vice President of AstraZeneca's Oncology Business Unit.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction